United Therapeutics (UTHR) Notice: 1,800 Restricted Shares to Be Sold
Rhea-AI Filing Summary
UNITED THERAPEUTICS (UTHR) Form 144 summary: A holder intends to sell 1,800 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate aggregate market value of $747,767.70. The shares were acquired on 07/13/2024 as restricted stock from the issuer and were fully paid on that date. The filing lists an approximate total outstanding share count of 45,226,262 and an approximate sale date of 09/19/2025. No securities were reported sold by the same person in the past three months. The filer certifies they are unaware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR Proposed sale is a limited number of restricted shares executed through a broker; impact appears routine.
The filing documents a planned disposition of 1,800 restricted common shares with an aggregate market value of $747,767.70, to be executed via Morgan Stanley Smith Barney on NASDAQ around 09/19/2025. The shares were originally granted by the issuer on 07/13/2024 and fully paid the same day. No other sales by this person are reported in the prior three months. From a trading-flow perspective, this is a single-holder notice required by Rule 144 and, by itself, does not provide information about company performance.
TL;DR This is a compliance filing documenting a planned sale of restricted stock; governance implications are procedural.
The notice confirms the securities were acquired as restricted stock from the issuer and that the seller represents no undisclosed material adverse information exists. The use of a broker and the absence of other recent sales suggest the filer is following Rule 144 procedures for public disposition. The filing does not disclose any changes in officer/director status, control transfers, or additional governance actions.